|
1
|
Allendorf DJ, Bordoni RE, Grant SC, Saleh
MN, Reddy VB, Jerome ML, Dixon PM, Miley DK, Singh KP and Robert F:
Phase I/IIa study of sequential chemotherapy regimen of
bendamustine/irinotecan followed by etoposide/carboplatin in
untreated patients with extensive disease small cell lung cancer
(EDSCLC). Cancer Chemother Pharmacol. 76:949–955. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Balabko L, Andreev K, Burmann N, Schubert
M, Mathews M, Trufa DI, Reppert S, Rau T, Schicht M, Sirbu H, et
al: Increased expression of the Th17-IL-6R/pSTAT3/BATF/RorγT-axis
in the tumoural region of adenocarcinoma as compared to squamous
cell carcinoma of the lung. Sci Rep. 4:73962014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Köhler J and Schuler M: LUX-Lung 3:
Redundancy, toxicity or a major step forward? Afatinib as
front-line therapy for patients with metastatic EGFR-mutated lung
cancer. Future Oncol. 10:533–540. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang S, Zhang B, Li C, Cui C, Yue D, Shi
B, Zhang Q, Zhang Z, Zhang X and Wang C: Prognostic value of number
of negative lymph node in patients with stage II and IIIa non-small
cell lung cancer. Oncotarget. 8:79387–79396. 2017.PubMed/NCBI
|
|
5
|
Belani CP, Yamamoto N, Bondarenko IM,
Poltoratskiy A, Novello S, Tang J, Bycott P, Niethammer AG,
Ingrosso A, Kim S and Scagliotti GV: Randomized phase II study of
pemetrexed/cisplatin with or without axitinib for non-squamous
non-small-cell lung cancer. BMC Cancer. 14:2902014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shen H, Du G, Liu Z, Bao J, Yu Q, Jia C,
Liang X and Shan L: Assessment and prognostic analysis of EGFR
mutations or/and HER2 overexpression in Uygur's non-small cell lung
cancer. Int J Clin Exp Med. 8:22300–22309. 2015.PubMed/NCBI
|
|
7
|
Li N, Li H, Su F, Li J, Ma X and Gong P:
Relationship between epidermal growth factor receptor (EGFR)
mutation and serum cyclooxygenase-2 Level, and the synergistic
effect of celecoxib and gefitinib on EGFR expression in non-small
cell lung cancer cells. Int J Clin Exp Pathol. 8:9010–9020.
2015.PubMed/NCBI
|
|
8
|
Lococo F, Paci M, Rapicetta C, Rossi T,
Sancisi V, Braglia L, Cavuto S, Bisagni A, Bongarzone I, Noonan DM,
et al: Preliminary evidence on the diagnostic and molecular role of
circulating soluble EGFR in non-small cell lung cancer. Int J Mol
Sci. 16:19612–19630. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Furcht CM, Muñoz Rojas AR, Nihalani D and
Lazzara MJ: Diminished functional role and altered localization of
SHP2 in non-small cell lung cancer cells with EGFR-activating
mutations. Oncogene. 32:2346–2355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Metzger B, Chambeau L, Begon DY, Faber C,
Kayser J, Berchem G, Pauly M, Boniver J, Delvenne P, Dicato M and
Wenner T: The human epidermal growth factor receptor (EGFR) gene in
European patients with advanced colorectal cancer harbors
infrequent mutations in its tyrosine kinase domain. BMC Med Genet.
12:1442011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang X, Fan J, Li Y, Lin S, Shu P, Ni J,
Qin S and Zhang Z: Polymorphisms in epidermal growth factor
receptor (EGFR) and AKT1 as possible predictors of clinical outcome
in advanced non-small-cell lung cancer patients treated with EGFR
tyrosine kinase inhibitors. Tumour Biol. 37:1061–1069. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) methods. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim JH, Kim HS and Kim BJ: Prognostic
value of smoking status in non-small-cell lung cancer patients
treated with immune checkpoint inhibitors: A metaanalysis.
Oncotarget. 8:93149–93155. 2017.PubMed/NCBI
|
|
14
|
Cimino D, De Pittà C, Orso F, Zampini M,
Casara S, Penna E, Quaglino E, Forni M, Damasco C, Pinatel E, et
al: miR148b is a major coordinator of breast cancer progression in
a relapse-associated microRNA signature by targeting ITGA5, ROCK1,
PIK3CA, NRAS, and CSF1. FASEB J. 27:1223–1235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ardizzoni A, Manegold C, Debruyne C,
Gaafar R, Buchholz E, Smit EF, Lianes P, ten Velde G, Bosquee L,
Legrand C, et al: European organization for research and treatment
of cancer (EORTC) 08957 phase II study of topotecan in combination
with cisplatin as second-line treatment of refractory and sensitive
small cell lung cancer. Clin Cancer Res. 9:143–150. 2003.PubMed/NCBI
|
|
16
|
Du B, Wang Z, Zhang X, Feng S, Wang G, He
J and Zhang B: MicroRNA-545 suppresses cell proliferation by
targeting cyclin D1 and CDK4 in lung cancer cells. PLoS One.
9:e880222014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F,
Bao G, Kong H, Ge C, Zhang F, et al: miRNA-200c inhibits invasion
and metastasis of human non-small cell lung cancer by directly
targeting ubiquitin specific peptidase 25. Mol Cancer. 13:1662014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao X, He W, Li J, Huang S, Wan X, Luo H
and Wu D: MiRNA-125b inhibits proliferation and migration by
targeting SphK1 in bladder cancer. Am J Transl Res. 7:2346–2354.
2015.PubMed/NCBI
|
|
19
|
Liao WT, Li TT, Wang ZG, Wang SY, He MR,
Ye YP, Qi L, Cui YM, Wu P, Jiao HL, et al: microRNA-224 promotes
cell proliferation and tumor growth in human colorectal cancer by
repressing PHLPP1 and PHLPP2. Clin Cancer Res. 19:4662–4672. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang XC, Du LQ, Tian LL, Wu HL, Jiang XY,
Zhang H, Li DG, Wang YY, Wu HY, She Y, et al: Expression and
function of miRNA in postoperative radiotherapy sensitive and
resistant patients of non-small cell lung cancer. Lung Cancer.
72:92–99. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin K, Cheng J, Yang T, Li Y and Zhu B:
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through
inhibiting NF-κB. Biochem Biophys Res Commun. 463:95–101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhen Q, Liu J, Gao L, Liu J, Wang R, Chu
W, Zhang Y, Tan G, Zhao X and Lv B: MicroRNA-200a targets EGFR and
c-Met to inhibit migration, invasion and gefitinib resistance in
non-small cell lung cancer. Cytogenet Genome Res. 146:1–8. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X, Pesakhov S, Weng A, Kafka M, Gocek
E, Nguyen M, Harrison JS, Danilenko M and Studzinski GP: ERK 5/MAPK
pathway has a major role in 1α,25-(OH)2 vitamin D3-induced terminal
differentiation of myeloid leukemia cells. J Steroid Biochem Mol
Biol. 144:223–227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Paolo M, Assunta S, Antonio R, Claudia SP,
Anna BM, Clorinda S, Francesca C, Fortunato C and Cesare G:
Selumetinib in advanced non small cell lung cancer (NSCLC)
harbouring KRAS mutation: Endless clinical challenge to KRAS-mutant
NSCLC. Rev Recent Clin Trials. 8:93–100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saito N, Mine N, Kufe DW, Von Hoff DD and
Kawabe T: CBP501 inhibits EGF-dependent cell migration, invasion
and epithelial-to-mesenchymal transition of non-small cell lung
cancer cells by blocking KRas to Calmodulin binding. 8:1–74018.
2017.
|
|
26
|
Wainstein E and Seger R: The dynamic
subcellular localization of ERK: Mechanisms of translocation and
role in various organelles. Curr Opin Cell Biol. 39:15–20. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu BB, Luo L, Liu XL, Geng D, Liu Q and
Yi LT: 7-Chlorokynurenic acid (7-CTKA) produces rapid
antidepressant-like effects: Through regulating hippocampal
microRNA expressions involved in TrkB-ERK/Akt signaling pathways in
mice exposed to chronic unpredictable mild stress.
Psychopharmacology (Berl). 232:541–550. 2015. View Article : Google Scholar : PubMed/NCBI
|
